HopeStage
Back to all studies
RecruitingNCT07363577

LB-102 compared with placebo for acute schizophrenia

About this titleRead the official source — NCT07363577
Medication studyAges 18–65United States
The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

What will I do during this study?

Adults aged 18–65 with an acute episode of schizophrenia may be eligible. This Phase 3 study randomly assigns participants to six weeks of LB-102 at 50 mg, LB-102 at 100 mg, or placebo (an inactive comparison treatment). Participants must be willing to stay in hospital for the study. Researchers are assessing the medicine against placebo; the study has not established its effects or safety.

Listed locations
Bentonville and 12 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: March 25, 2026
Recruitment status
Recruiting
Enrollment listed in the registry
456
Sponsor
LB Pharmaceuticals Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT07363577
Official title
Show the full official title

A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB 102 in the Treatment of Adult Patients With Acute Schizophrenia

Recruitment & locations

Currently recruiting

Bentonville · Little Rock · Culver City

9 more locations
  • Garden Grove
  • Lemon Grove
  • Riverside
  • Boynton Beach
  • Miami Lakes
  • Snellville
  • Chicago
  • St Louis
  • North Canton

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is LB Pharmaceuticals Inc.

Does this study involve medication?

Yes. The study involves medication, including LB-102 (50 mg tablet) and LB-102 (100 mg tablet).

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies